ICBMT 2023 THE 7th INTERNATIONAL CONGRESS OF BMT 2023 28th ANNUAL CONGRESS OF KSBMT Exploring New Insights into the Future of HSCT and Cellular Therapy August 31(Thu) – September 2(Sat), 2023 BEXCO, BUSAN

<
>

ICBMT Photo Gallery

Quick

News & Notice

News & Notices

Invited Speakers

prev next
  • PS01 New Insights and Challenges in Managing Chronic GVHD Stephanie Lee Fred Hutch Cancer Center, USA CV
  • PL01-1 Mesenchymal Stem Cell Therapy Katarina LeBlanc Karolinska Institutet, Sweden CV
  • PL01-2 NK-Cell Based Therapies Dan Kaufman UC San Diego, USA CV
  • PL02-1 How to Improve the Outcome of CBT Vanderson Rocha The University of São Paulo, Brazil CV
  • PL02-1 Trends and Future of the HSCT Using Mismatched Donors Anna Sureda Catalan Institute of Oncology, Spain CV
  • PL03-1 Biology and Strategy to Prevent and Treat Post-HSCT Relapse in Myeloid Diseases John F. DiPersio Washington University in St. Louis, USA CV
  • SS01-1 Optimal Strategy of Transplantation in Fanconi Anemia Jae Wook Lee The Catholic University of Korea, Korea CV
  • SS01-2 Choice of Appropriate Conditioning Regimens for Aplastic Anemia Nelli Bejanyan H. Lee Moffitt Cancer Center and Research Institute, USA CV
  • SS01-3 Finding Mutational Landscape SAA & Implicating It to the Treatment William Hogan Mayo Clinic, USA CV
  • SS02-1 Novel Strategies to Overcome Relapsed/Refractory Multiple Myeloma Suzanne Trudel University of Toronto, Canada CV
  • SS02-2 Novel Immunotherapy for Relapsed and Refractory B-Cell Lymphomas Won Seog Kim Sungkyunkwan University School of Medicine, Korea CV
  • SS02-3 Best Positioning of Immunotherapy in Adult B-Cell ALL Mark R. Litzow Mayo Clinic, USA
  • SS03-1 Immune Reconstitution after HSCT Stefan Nierkens University Medical Centre Utrecht, Netherlands CV
  • SS03-2 Proteomics in HSCT Sophie Paczesny Melvin and Bren Simon Cancer Center, USA CV
  • SS03-3 GVHD Immunology Geoffrey R. Hill Fred Hutchinson Cancer Research Center, USA
  • SS04-1 NK Cells in Autologous Stem Cell Transplantation Hareth Nahi Karolinska Institutet, Sweden
  • SS04-2 Gene Editing in Autologous Stem Cell Transplantation Matthew H Porteus Stanford University, USA
  • SS04-3 Autologous Stem Cell Transplantation in Solid Tumor Ji won Lee Sungkyunkwan University School of Medicine, Korea
  • SS05-1 New Insights into the Pathophysiology of GVHD Takanori Teshima Hokkaido University Hospital, Japan CV
  • SS05-2 Predicting GVHD: From Biomarkers to Clinical Risk Score Margaret MacMilan University of Minnesota, USA
  • SS05-3 Post-Transplant Cyclophosphamide as the New Standard for GVHD Prophylaxis Byung-Su Kim The Catholic University of Korea, Korea
  • SS06-1 Next Generation Immunotherapy in Multiple Myeloma Thomas Martin UCSF Medical Center, USA
  • SS06-2 Clinical Utility of CAR T-Cells in Earlier-Lines in Multiple Myeloma Saad Z Usmani Memorial Sloan Kettering Cancer Center, USA CV
  • SS06-3 Predictors of Response and Resistance of CAT-T or BsAb Therapy Yi Lin Mayo Clinic, USA
  • SS06-4 Prognostic Values of MRD Status after CAR-T or BsAb Therapies Bruno Paiva Clinica Universidad de Navarra, Spain
  • SS07-1 Recent Update of Cord Blood Transplantation in Adult Dong-Yeop Shin Seoul National University College of Medicine, Korea
  • SS07-2 Experience of Cord Blood Transplantation in Japan Satoshi Takahashi The University of Tokyo, Japan
  • SS07-3 Experience of Cord Blood Transplantation in USA Filippo Milano University of Washington, USA CV
  • SS07-4 The Status of Cord Blood Banks (CBBs) for Unrelated Hematopoietic Stem Cell Transplantation (UR-HCT) & its Management of CBBs in Korea Jung Lim Lee Daegu Fatima Hospital, Korea CV
  • SS08-1 The Bone Marrow Microenvironment in Myeloid Leukemia Daniela S. Krause Goethe University Frankfurt, Germany
  • SS08-2 The Bone Marrow Microenvironment in Lymphoid Malignancy Sang-Woo Kim Pusan National University, Korea
  • SS08-3 The Bone Marrow Microenvironment in Multiple Myeloma Yoon Seok Choi Ajou Universitry School of Medicine, Korea
  • SS09-1 PTCY Alone vs. PTCY+ATG Combination in Haploidentical HSCT Hee Young Ju Sungkyunkwan University School of Medicine, Korea
  • SS09-2 How T and NK Cells Mediate the GVL Effect without GVHD in the Haploidentical HSCT: Insight Biological Mechanisms Loredana Ruggeri Perugia University School of Medicine, Italy
  • SS09-3 Regimen Intensity and the Role of Total Body Irradiation in Haploidentical HSCT Jongheon Jung National Cancer Center, Korea
  • SS10-1 Electronic Health Record Use for Hematopoietic Cell Transplantation Research Sung Won Choi University of Michigan, Ann Arbor, USA CV
  • SS10-2 Artificial Intelligence in Stem Cell Transplantation Shahrukh K. Hashmi Mayo Clinic, UAE CV
  • SS10-3 Recent Advances in Artificial Intelligence in Healthcare Yoonjae Choi KAIST, Korea CV
  • SS11-1 Real World CAR-T in Pediatric Patients Theodore W. Laetsch The Children's Hospital of Philadelphia, USA
  • SS11-2 Pediatric Leukemia in the MRD Era (MRD Guided Treatment) Hiroto Inaba St. Jude Children's Research Hospital, USA
  • SS11-3 HSCT in Pediatric AML Daisuke Tomizawa National Center for Child Health and Development, Japan
  • SS12-1 The Role of MRD Monitoring and MRD-Directed Therapy in Patients with AML Jae-Sook Ahn Chonnam National University Medical School, Korea
  • SS12-2 Venetoclax Combination Therapy as a Bridging for HSCT in Elderly or Unfit AML Maximilian Stahl Dana-Farber Cancer Institute, USA
  • SS12-3 HSCT for Elderly Patients With AML or MDS: Geriatric Assessment and Transplant Decision Gi June Min The Catholic University of Korea, Korea
  • SS13-1 Tumor Microenvironment in CAR T-Cell Therapy Saad S. Kenderian Mayo Clinic, USA
  • SS13-2 Engineered T Cells Produced From “Alternative Cellular Sources” Hiroshih Kawamoto Kyoto University, Japan
  • SS13-3 TCR-T Cells for Cancer Premal D. Lulla Baylor College of Medicine, USA
  • SS13-4 Revolutionizing Solid Tumor Immunotherapy with CAR-NK Cells Mihue Jang KIST, Korea
  • JS01-1 Cell Therapy Hyunsoo Cho Yonsei University College of Medicine, Korea
  • JS01-2 Pediatrics Perspective Rayne Rouce Baylor College of Medicine, USA
  • JS01-3 Stem Cell Transplant Julie Vose University of Nebraska Medical Center, USA
  • JS02-1 Cellular Therapies in Multiple Myeloma: Revolutionizing Treatment Approaches Ahmet Kursat Gunes Ankara City Hospital, Türkiye
  • JS02-2 Bispecific Antibodies in Multiple Myeloma Ja Min Byun Seoul National University College of Medicine, Korea
  • JS03-1 The Role of Allogeneic Stem Cell Transplantation in Philadelphia positive ALL in the Era of Targeted Therapy Sebastian Giebel Maria Sklodowska-Curie National Research Institute of Oncology, Poland
  • JS03-2 CAR T-Cells in Pediatric Patients with B-cell Acute Lymphoblastic Leukemia Vanderson Rocha The University of São Paulo, Brazil
  • JS03-3 Hematopoietic Stem Cell Transplantation and CAR T for Pediatric ALL Hyery Kim University of Ulsan College of Medicine, Korea
  • JS03-4 Treatment of Adult Acute Lymphoblastic Leukemia in Korea Han-Seung Park University of Ulsan College of Medicine, Korea
  • JS05-1 Cell & Gene Therapy Market & CDMO Business in Korea Sun Jae Kwon ENCell Co., Ltd., Korea
  • JS05-2 AAV Vectors as the Most Popular Viral Gene Delivery System Keerang Park CdmoGen Co., Ltd., Korea
  • JS05-3 Engaging Cell and Gene Therapy Companies in Collaboration Steve oh Independent Cell Therapy Leader, Singapore
  • JS06-1 Prognostic Factors in Allogeneic Hematopoietic Stem Cell Transplantation for Adults with Myelodysplastic Neoplasms: Retrospective Studies From a Nationwide Registry Data in Japan Hidehiro Itonaga Nagasaki University, Japan CV
  • JS06-2 Hematopoietic Cell Transplantation for Pediatric Myelodysplastic Syndrome in Japan: JSTCT Pediatric MDS Working Group Study Shohei Yamamoto Tokai University, Japan
  • JS06-3 TBD Joon Ho Moon Kyungpook National University School of Medicine, Korea
  • JS06-4 Characteristics and Clinical Outcomes of Juvenile Myelomonocytic Leukemia in Korea Eun Sang Yi Korea University College of Medicine, Korea CV
  • JS04-1 TBD Bor Sheng Ko National Taiwan University Hospital, Taiwan
  • JS04-2 CAR T-Cell therapy in China He huang The First Affiliated Hospital, Zhejiang University School of Medicine, China
  • JS04-3 Current Status and Future Directions in CAR T-Cell Therapy for Lymphoma in Korea Dok Hyun Yoon University of Ulsan College of Medicine, Korea
  • JS04-4 Current status and challenges of CAR-T therapy for hematopoietic malignancies Koji Kato Kyushu University Graduate School of Medical Sciences, Japan
  • ES01-1 Overview of the Endothelial Dysfunction after HSCT Junshik Hong Seoul National University College of Medicine, Korea
  • ES01-2 Review of Tma Based on the Harmonized Consensus Opinion Sung Han Kang University of Ulsan College of Medicine, Korea
  • ES01-3 Veno-Occlusive Disease / Sinusoidal Obstruction Syndrome Ka-Won Kang Korea University College of Medicine, Korea CV
  • ES02-1 High-Dose Conditioning Regimens: Tbi-Based vs. High-Dose Chemotherapy Jae-Ho Yoon The Catholic University of Korea, Korea
  • ES02-2 Dose Intensity for Conditioning in Allogeneic Hematopoietic Cell Transplantation: Reduced Intensity Conditioning Versus. Myeloablative Conditioning Yunsuk Choi University of Ulsan College of Medicine, Korea
  • ES02-3 Novel Conditioning Regimens for Hematopoietic Cell Transplantation Sung Nam Lim Inje University College of Medicine, Korea
  • ES03-1 How I Prevent and Manage COVID-19 Infection after HSCT? Pyoeng Gyun Choe Seoul National University College of Medicine, Korea
  • ES03-2 How I Prevent and Manage CMV And Herpes Infection after HSCT? Yae-Jean Kim Sungkyunkwan University School of Medicine, Korea
  • ES03-3 How I Prevent and Manage HBV Reactivation after HSCT? Su Jong Yu Seoul National University College of Medicine, Korea
  • ES04-1 Clinical Diagnosis and Prophylaxis of Chronic GVHD Eun-Ji Choi University of Ulsan College of Medicine, Korea
  • ES04-2 Novel Treatment and Sequence for Steroid-Refractory Chronic GVHD Eunyoung Lee National Cancer Center, Korea
  • ES04-3 Multidisciplinary Care to Improve Outcome of Chronic GVHD Seo-Yeon Ahn Chonnam National University Medical School, Korea
  • DS01-1 Mismatched Unrelated Hematopoietic Stem Cell Transplantation Sung-Hoon Jung Chonnam National University Medical School, Korea
  • DS01-2 Haploidentical Jae-Cheol Jo University of Ulsan College of Medicine, Korea
  • DS02-1 Consolidative SCT Jae Won Yoo The Catholic University of Korea, Korea
  • DS02-2 Not after CAR T-Cell in ALL Seung-min Hahn Yonsei University College of Medicine, Korea
  • NS01-1 Global Trend Utilizing Real-World Data (RWD) Seung Hoon Han The Catholic University of Korea, Korea
  • NS01-2 From RWD To Real-World-Evidence (RWE) in Hematologic Disease Sung-Soo Park The Catholic University of Korea, Korea
  • NS01-3 Improving Diabetes Treatment Access and Outcomes Using Integrating Technology - Diabetes Mobile Apps - Kang Hee Sim Sungkyunkwan University, Korea
  • NS01-4 Introduction to Digital Therapeutics for Real-Time Symptom Monitoring and Providing Severity-Dependent Patient Advice Guiding Self Management or Medical Contact for Oncology Patients Jihyon Youn All Round Doctors, Korea
  • NS02-1 Precision Medicine in Hematologic Disease Sheehyun Kim Seoul National University College of Medicine, Korea
  • NS02-2 Clinical Experience of Covid-19 in Hematologic Patients Chang Kyung Kang Seoul National University College of Medicine, Korea
  • NS02-3 Emergency preparedness and response in nursing during unpredictable pandemic Jae Geum Ryu Chodang University, Korea
  • LS01 How Do I Avoid Complication of Chronic GVHD? Bipin Savani Vanderbilt University Medical Center, USA CV
  • LS02 Oral Azacitidine Maintenance Therapy after Intensive Chemotherapy for Transplant-Ineligible AML Patients Michael Pfeilstöcker Hanusch Hospital, Austria
  • LS03 Tafasitamab Efficacy and Safety in DLBCL Gilles Salles Memorial Sloan Kettering Cancer Center, USA CV
  • LS04 What is Missing in Hematology? Dong-Gun Lee The Catholic University of Korea, Korea
  • LS05 CMV Prophylaxis in Letermovir Era Jeong-Ok Lee Seoul National University College of Medicine, Korea
  • LS06 Mogamulizumab for the Treatment of MF and SS Youn H Kim Stanford University School of Medicine, USA
  • LS07 Emerging Strategies for Elderly and Unfit AML Patients in R/R Setting Naval Daver MD Anderson Cancer Center, USA
  • LS08 Resistant Mechanisms of Daratumumab and Immunotherapy in MM Treatment Sophia Adamia Dana-Farber Cancer Institute, Harvard Medical School, USA
  • LS09 TBD Corey Cutler Dana-Farber / Harvard Cancer Center, USA CV

Organized by

Supported by

Sponsors

  • >